Alembic has reported results for fourth quarter and year ended March 31, 2021.
The company has reported a fall of 93.45% in its net profit at Rs 3.63 crore for the quarter under review as compared to Rs 55.46 crore for the same quarter in the previous year. Total income of the company decreased by 55.92% at Rs 30.26 crore for Q4FY21 as compared Rs 68.65 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported a fall of 37.68% in its net profit and share of associate’s profit at Rs 71.94 crore for the quarter under review as compared to Rs 115.43 crore for the same quarter in the previous year. Total income of the company decreased by 55.41% at Rs 30.66 crore for Q4FY21 as compared Rs 68.76 crore for the corresponding quarter previous year.
For the year ended March 31, 2021, the company has reported a fall of 85.72% in its net profit at Rs 13.36 crore as compared to Rs 93.55 crore for the previous year. Total income of the company decreased by 50.48% at Rs 82.77 crore for year under review as compared to Rs 167.16 crore for year ended March 31, 2020.
For the year ended March 31, 2021, on the consolidated basis, the company has reported a rise of 4.17% in its net profit and share of associate’s profit at Rs 342.84 crore as compared to Rs 329.12 crore for the previous year. However, total income of the company decreased by 49.93% at Rs 83.79 crore for year under review as compared to Rs 167.33 crore for year ended March 31, 2020.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |